Search | CFR Journal

Cardiac Failure Review

Journal Impact Factor: 5.7

Back to Main Menu

View all platforms

Content for healthcare professionals only

Search results

Effects of GLP-1 Receptor Agonists in Heart Failure Patients

Review Article

Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure

ESC HFA 25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function

Video

Author(s): Safia Chatur Added: 12 months ago

ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Kidney Metabolic

Heart Failure

ESC HF 25: Kidney Function Trajectories Before and After HF Hospitalisation

Video

Author(s): Nicolas Girerd Added: 12 months ago

ESC HF 25 - Real-world findings suggest kidney function decline could precede heart failure events by up to a year.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses real-world findings from pooled trials EPHESUS, EMPHASIS-HF and BARCELONA. The study investigated if longitudinal changes in kidney function could help identify patients with HFrEF at a higher risk of… View more

Cardiovascular Kidney Metabolic

Heart Failure

HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status

Video

Author(s): Mikhail Kosiborod Added: 1 year ago

HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic

Increased Systolic Blood Pressure Variability Over Time Linked to Higher Risk of CVD, CKD, and Death

News

Added: 10 months ago Source: Radcliffe CVRM

AUTHOR: Liam ONeillWhile elevated systolic blood pressure variability (SBPV) is a known risk factor for adverse health outcomes, new research published in the European Heart Journal suggests that the change in SBPV over time is also a critical prognostic indicator. The study found that an increase in visit-to-visit SBPV over a 10-year period was significantly associated with a higher risk of… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic

EASD 24: Prespecified Analysis from the SELECT Trial

Video

Author(s): Helen Colhoun Added: 1 year ago

EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.Findings showed that participants in the study with reduced eGFR and/or… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic

Vutrisiran Attenuates Cardiac Decline in ATTR-CM, HELIOS-B Analysis Shows

News

Added: 9 months ago Source: Radcliffe Cardiology

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal disease characterised by the deposition of amyloid fibrils in the heart. A new analysis from the HELIOS-B trial has found that key echocardiographic measures are strong predictors of clinical outcomes and that the RNA interference (RNAi) therapeutic vutrisiran attenuates the decline in cardiac function in this patient… View more

Imaging & Diagnostics

Heart Failure